Global Stroke Market - Industry Trends and Forecast to 2030

Description

List of Tables

Global Stroke market is projected to register a CAGR of 7.5% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation

Global Stroke Market, By Type (Ischemic Stroke, Transient Ischemic Attack (TIA) and Hemorrhage Stroke), Diagnosis (Imaging Test, Blood Test, Echocardiogram, Lumbar Puncture, and Other), Treatment (Medication, Other Therapy, and Surgery), Gender (Female and Male), End-User (Hospitals & Clinics, Specialty Clinics, Ambulatory Surgical Centers, Homecare, Laboratories and Others), Distribution Channel (Direct Tender, Retail Sales And Online Sales) Country (U.S., Canada, Mexico, Germany, U.K., France, Russia, Italy, Spain, Turkey, Poland, Belgium, Netherlands, Switzerland, Denmark, Sweden, Norway, Finland, Rest of Europe, China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, UAE, South Africa, Egypt, Qatar, Kuwait, Oman, Bahrain and Rest of Middle East And Africa) - Industry trends and forecast to 2030.

Overview of Global Stroke Market Dynamics

Drivers
Rising incidences of stroke
Increasing number of patients with hypertension and coronary heart diseases
Restraints
High cost associated with treatment of stroke
Side-effects associated with medication
Opportunities
Expansion of telemedicine and remote monitoring
Innovative therapies in pipeline for stroke treatment

Market Players

Some of the major market players operating in the global stroke market are:

Bristol-Myers Squibb Company
Boehringer Ingelheim International GmbH.
F. Hoffmann-La Roche Ltd
DAIICHI SANKYO COMPANY, LIMITED.
Sanofi
Johnson & Johnson Services, Inc.
Bayer AG
Sandoz AG
Pfizer Inc.
Medtronic
Abbott
Viatris Inc.
AstraZeneca
Penumbra, Inc.
GLENMARK PHARMACEUTICALS LTD
Fresenius Kabi USA
Teva Pharmaceuticals USA, Inc.
Lupin
Amneal Pharmaceuticals LLC.
Oxford Laboratories Pvt. Ltd.

1 INTRODUCTION 81

1.1 OBJECTIVES OF THE STUDY 81
1.2 MARKET DEFINITION 81
1.3 OVERVIEW OF THE GLOBAL STROKE MARKET 81
1.4 LIMITATIONS 83
1.5 MARKETS COVERED 83

2 MARKET SEGMENTATION 88

2.1 MARKETS COVERED 88
2.2 GEOGRAPHICAL SCOPE 89
2.3 YEARS CONSIDERED FOR THE STUDY 90
2.4 CURRENCY AND PRICING 90
2.5 DBMR TRIPOD DATA VALIDATION MODEL 91
2.6 MULTIVARIATE MODELLING 94
2.7 TYPE LIFELINE CURVE 95
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 96
2.9 DBMR MARKET POSITION GRID 97
2.10 MARKET APPLICATION COVERAGE GRID 98
2.11 VENDOR SHARE ANALYSIS 99
2.12 SECONDARY SOURCES 100
2.13 ASSUMPTIONS 100

3 EXECUTIVE SUMMARY 101

4 PREMIUM INSIGHTS 104

4.1 PESTEL'S MODEL 107
4.2 PORTER'S 5 FORCES 108

5 EPIDEMIOLOGY 109

6 GLOBAL STROKE MARKET, REGULATORY FRAMEWORK 110

6.1 REGULATION IN U.S. 110
6.2 REGULATION IN EUROPE 111
6.3 REGULATION IN CHINA 112
6.4 REGULATION IN JAPAN 113
6.5 REGULATION IN SOUTH AFRICA 114

7 MARKET OVERVIEW 115

7.1 DRIVERS 117
- 7.1.1 RISING INCIDENCES OF STROKE 117
- 7.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES 118
- 7.1.3 INCREASING DIABETIC AND OBESE POPULATION 119
- 7.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY FOR STROKE TREATMENT 120
7.2 RESTRAINTS 121
- 7.2.1 HIGH COST ASSOCIATED WITH TREATMENT OF STROKE 121
- 7.2.2 SIDE-EFFECTS ASSOCIATED WITH MEDICATION 122
7.3 OPPORTUNITIES 123
- 7.3.1 EXPANSION OF TELEMEDICINE AND REMOTE MONITORING 123
- 7.3.2 INNOVATIVE THERAPIES IN PIPELINE FOR STROKE TREATMENT 123
7.4 CHALLENGES 124
- 7.4.1 INACCURATE DIAGNOSIS OF STROKES S 124
- 7.4.2 COMPLICATIONS IN MANAGING STROKE IN PATIENTS WITH MULTIPLE CHRONIC CONDITIONS 125

8 GLOBAL STROKE MARKET, BY TYPE 126

8.1 OVERVIEW 127
8.2 ISCHEMIC STROKE 130
- 8.2.1 THROMBOTIC (CEREBRAL THROMBOSIS) 131
- 8.2.2 EMBOLIC (CEREBRAL EMBOLISM) 131
8.3 HEMORRHAGIC STROKE 132
- 8.3.1 SUBARACHNOID HEMORRHAGE 133
- 8.3.2 INTRACEREBRAL HEMORRHAGE 133
8.4 TRANSIENT ISCHEMIC ATTACK (TIA) 133

9 GLOBAL STROKE MARKET, BY TREATMENT 134

9.1 OVERVIEW 135
9.2 MEDICATION 138
- 9.2.1 BY CLASS 139
  - 9.2.1.1 BLOOD PRESSURE MEDICINES 140
    - 9.2.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 141
    - 9.2.1.1.1.1 RAMIPRIL 141
    - 9.2.1.1.1.2 LISINOPRIL 141
    - 9.2.1.1.1.3 ENALAPRIL 141
    - 9.2.1.1.1.4 PERINDOPRIL 141
    - 9.2.1.1.1.5 OTHER 142

9.2.1.1.2 DIURETICS 142
9.2.1.1.2.1 INDAPAMIDE 142
9.2.1.1.2.2 BENDROFLUMETHIAZIDE 142
9.2.1.1.2.3 SPIRONOLACTONE 142
9.2.1.1.2.4 AMILORIDE 143
9.2.1.1.2.5 OTHER 143
9.2.1.1.3 CALCIUM CHANNEL BLOCKERS 143
9.2.1.1.3.1 AMLODIPINE 143
9.2.1.1.3.2 NIFEDIPINE 143
9.2.1.1.3.3 VERAPAMIL 144
9.2.1.1.3.4 NICARDIPINE 144
9.2.1.1.3.5 FELODIPINE 144
9.2.1.1.3.6 NIMODIPINE 144
9.2.1.1.3.7 OTHER 144
9.2.1.1.4 BETA BLOCKERS 145
9.2.1.1.4.1 ATENOLOL 145
9.2.1.1.4.2 BISOPROLOL 145
9.2.1.1.4.3 LABETOLOL 145
9.2.1.1.4.4 OTHER 145
9.2.1.1.5 ALPHA BLOCKERS 146
9.2.1.1.5.1 DOXAZOSIN 146
9.2.1.1.5.2 OTHER 146
9.2.1.1.6 OTHERS 146

9.2.1.1 ANTIPLATELET DRUGS 147
- 9.2.1.1.1 ASPIRIN 147
- 9.2.1.1.2 CLOPIDOGREL 147
- 9.2.1.1.3 DIPYRIDAMOLE 147
- 9.2.1.1.4 TICLOPIDINE 147
- 9.2.1.1.5 OTHERS 147
9.2.1.2 ANTICOAGULANTS 148
- 9.2.1.2.1 WARFARIN 148
- 9.2.1.2.2 APIXABAN 148
- 9.2.1.2.3 DABIGATRAN 148
- 9.2.1.2.4 HEPARIN 148
- 9.2.1.2.5 RIVAROXABAN 149
- 9.2.1.2.6 OTHERS 149
9.2.1.3 TISSUE PLASMINOGEN ACTIVATOR (TPA) 149
- 9.2.1.3.1 ALTEPLASE 149
- 9.2.1.3.2 TENECTEPLASE 149
- 9.2.1.3.3 RETEPLASE 149
- 9.2.1.3.4 ANISTREPLASE 150
- 9.2.1.3.5 OTHERS 150
9.2.1.4 STATINS 150
- 9.2.1.4.1 ATORVASTATIN 150
- 9.2.1.4.2 SIMVASTATIN 150
- 9.2.1.4.3 LOVASTATIN 150
- 9.2.1.4.4 ROSUVASTATIN 151
- 9.2.1.4.5 FLUVASTATIN 151
- 9.2.1.4.6 PRAVASTATIN 151
- 9.2.1.4.7 PITAVASTATIN 151
- 9.2.1.4.8 OTHERS 151
9.2.1.5 VITAMIN K 151
9.2.1.6 SUPPORTIVE MEDICATION 152
- 9.2.1.6.1 NUTRITIONAL SUPPLEMENTS 152
- 9.2.1.6.2 ANTIPYRETICS 152
- 9.2.1.6.3 OTHERS 152

9.2.2 BY DRUG TYPE 153
- 9.2.2.1 GENERICS 153
- 9.2.2.2 BRANDED 154
  - 9.2.2.2.1 ELIQUIS 154
  - 9.2.2.2.2 PRADAXA 154
  - 9.2.2.2.3 ACTIVASE 154
  - 9.2.2.2.4 ASPIRIN 155
  - 9.2.2.2.5 PLAVIX 155
  - 9.2.2.2.6 AGGRENOX 155
  - 9.2.2.2.7 OTHERS 155
9.2.3 BY ROUTE OF ADMINISTRATION 156
- 9.2.3.1 ORAL 156
  - 9.2.3.1.1 TABLET 157
  - 9.2.3.1.2 CAPSULES 157
  - 9.2.3.1.3 Others 157
- 9.2.3.2 PARENTERAL 158
  - 9.2.3.2.1 INTRAVENOUS 158
  - 9.2.3.2.2 SUBCUTANEOUS 158
- 9.2.3.3 OTHERS 158
9.2.4 BY MODE OF PURCHASE 159
- 9.2.4.1 PRESCRIPTION 159
- 9.2.4.2 OVER THE COUNTER (OTC) 159
9.2.5 BY THERPAY TYPE 160
- 9.2.5.1 COMBINATION THERAPY 160
- 9.2.5.2 MONOTHERAPY 160

9.3 SURGERY 161
- 9.3.1 EMBOLIC COILS 162
- 9.3.2 ASPIRATION CATHETERS 162
- 9.3.3 STENT RETRIEVER 162
- 9.3.4 SURGICAL CLIPPING 162
- 9.3.5 OTHERS 162
9.4 OTHER THERAPY 163
- 9.4.1 PHYSICAL THERAPY 163
- 9.4.2 OCCUPATIONAL THERAPY 163
- 9.4.3 SPEECH THERAPY 164
- 9.4.4 OTHERS 164

10 GLOBAL STROKE MARKET, BY DIAGNOSIS 165

10.1 OVERVIEW 166
10.2 IMAGING TEST 169
- 10.2.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN 169
- 10.2.2 MAGNETIC RESONANCE IMAGING (MRI) 170
- 10.2.3 CAROTID ULTRASOUND 170
- 10.2.4 CEREBRAL ANGIOGRAM 170
10.3 BLOOD TEST 171
10.4 ECHOCARDIOGRAM 171
10.5 LUMBAR PUNCTURE 172
10.6 OTHERS 172

11 GLOBAL STROKE MARKET, BY GENDER 173

11.1 OVERVIEW 174
11.2 FEMALE 177
11.3 MALE 178

12 GLOBAL STROKE MARKET, BY END USER 179

12.1 OVERVIEW 180
12.2 HOSPITALS & CLINICS 183
12.3 SPECIALTY CLINICS 184
12.4 AMBULATORY SURGICAL CENTER 184
12.5 HOMECARE 185
12.6 LABORATORIES 185
12.7 OTHERS 186

13 GLOBAL STROKE MARKET, BY DISTRIBUTION CHANNEL 187

13.1 OVERVIEW 188
13.2 DIRECT 191
13.3 RETAIL 191
13.4 ONLINE 192

14 GLOBAL STROKE MARKET, BY REGION 193

14.1 OVERVIEW 194
14.2 NORTH AMERICA 197
- 14.2.1 U.S. 209
- 14.2.2 CANADA 220
- 14.2.3 MEXICO 231
14.3 EUROPE 242
- 14.3.1 GERMANY 255
- 14.3.2 U.K. 266
- 14.3.3 FRANCE 277
- 14.3.4 RUSSIA 289
- 14.3.5 ITALY 301
- 14.3.6 SPAIN 313
- 14.3.7 TURKEY 325
- 14.3.8 POLAND 336
- 14.3.9 BELGIUM 347
- 14.3.10 NETHERLANDS 358
- 14.3.11 SWITZERLAND 369
- 14.3.12 DENMARK 381
- 14.3.13 SWEDEN 392
- 14.3.14 NORWAY 403
- 14.3.15 FINLAND 415
- 14.3.16 REST OF EUROPE 427

14.4 ASIA-PACIFIC 428
- 14.4.1 CHINA 441
- 14.4.2 JAPAN 453
- 14.4.3 INDIA 465
- 14.4.4 AUSTRALIA 477
- 14.4.5 SOUTH KOREA 489
- 14.4.6 NEW ZEALAND 501
- 14.4.7 SINGAPORE 513
- 14.4.8 THAILAND 525
- 14.4.9 PHILIPPINES 537
- 14.4.10 MALAYSIA 549
- 14.4.11 INDONESIA 561
- 14.4.12 VIETNAM 573
- 14.4.13 TAIWAN 585
- 14.4.14 REST OF ASIA-PACIFIC 597
14.5 SOUTH AMERICA 598
- 14.5.1 BRAZIL 610
- 14.5.2 ARGENTINA 622
- 14.5.3 REST OF SOUTH AMERICA 633
14.6 MIDDLE EAST AND AFRICA 634
- 14.6.1 SAUDI ARABIA 644
- 14.6.2 U.A.E. 652
- 14.6.3 SOUTH AFRICA 660
- 14.6.4 EGYPT 668
- 14.6.5 QATAR 676
- 14.6.6 684
- 14.6.7 KUWAIT 684
- 14.6.8 OMAN 692
- 14.6.9 BAHRAIN 700
- 14.6.10 REST OF MIDDLE EAST AND AFRICA 708

15 GLOBAL STROKE MARKET, COMPANY LANDSCAPE 709

15.1 COMPANY SHARE ANALYSIS: GLOBAL 709
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 710
15.3 COMPANY SHARE ANALYSIS: EUROPE 711
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 712

16 SWOT ANALYSIS 713

17 COMPANY PROFILES 714

17.1 BRISTOL-MYERS SQUIBB COMPANY 714
- 17.1.1 COMPANY SNAPSHOT 714
- 17.1.2 REVENUE ANALYSIS 714
- 17.1.3 COMPANY SHARE ANALYSIS 715
- 17.1.4 PRODUCT PORTFOLIO 715
- 17.1.5 RECENT DEVELOPMENT 716
17.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 717
- 17.2.1 COMPANY SNAPSHOT 717
- 17.2.2 PRODUCT PORTFOLIO 717
- 17.2.3 COMPANY SHARE ANALYSIS 718
- 17.2.4 RECENT DEVELOPMENT 718
17.3 F. HOFFMANN-LA ROCHE LTD 719
- 17.3.1 COMPANY SNAPSHOT 719
- 17.3.2 REVENUE ANALYSIS 719
- 17.3.3 COMPANY SHARE ANALYSIS 720
- 17.3.4 PRODUCT PORTFOLIO 720
- 17.3.5 RECENT DEVELOPMENT 720
17.4 DAIICHI SANKYO COMPANY, LIMITED 721
- 17.4.1 COMPANY SNAPSHOT 721
- 17.4.2 REVENUE ANALYSIS 721
- 17.4.3 COMPANY SHARE ANALYSIS 722
- 17.4.4 PRODUCT PORTFOLIO 722
- 17.4.5 RECENT DEVELOPMENT 723
17.5 SANOFI 724
- 17.5.1 COMPANY SNAPSHOT 724
- 17.5.2 REVENUE ANALYSIS 724
- 17.5.3 COMPANY SHARE ANALYSIS 725
- 17.5.4 PRODUCT PORTFOLIO 725
- 17.5.5 RECENT DEVELOPMENT 725
17.6 ABBOTT 727
- 17.6.1 COMPANY SNAPSHOT 727
- 17.6.2 REVENUE ANALYSIS 727
- 17.6.3 PRODUCT PORTFOLIO 728
- 17.6.4 RECENT DEVELOPMENT 729

17.7 AMNEAL PHARMACEUTICALS LLC 730
- 17.7.1 COMPANY SNAPSHOT 730
- 17.7.2 REVENUE ANALYSIS 730
- 17.7.3 PRODUCT PORTFOLIO 731
- 17.7.4 RECENT DEVELOPMENT 731
17.8 ASTRAZENECA 732
- 17.8.1 COMPANY SNAPSHOT 732
- 17.8.2 REVENUE ANALYSIS 733
- 17.8.3 PRODUCT PORTFOLIO 733
- 17.8.4 RECENT DEVELOPMENT 733
17.9 BAYER AG 734
- 17.9.1 COMPANY SNAPSHOT 734
- 17.9.2 REVENUE ANALYSIS 735
- 17.9.3 PRODUCT PORTFOLIO 735
- 17.9.4 RECENT DEVELOPMENT 736
17.10 FRESENIUS SE & CO. KGAA 737
- 17.10.1 COMPANY SNAPSHOT 737
- 17.10.2 REVENUE ANALYSIS 737
- 17.10.3 PRODUCT PORTFOLIO 738
- 17.10.4 RECENT DEVELOPMENT 738
17.11 GLENMARK PHARMACEUTICALS LTD. 739
- 17.11.1 COMPANY SNAPSHOT 739
- 17.11.2 REVENUE ANALYSIS 740
- 17.11.3 PRODUCT PORTFOLIO 740
- 17.11.4 RECENT DEVELOPMENT 740
17.12 JOHNSON & JOHNSON SERVICES, INC. 742
- 17.12.1 COMPANY SNAPSHOT 742
- 17.12.2 REVENUE ANALYSIS 742
- 17.12.3 PRODUCT PORTFOLIO 743
- 17.12.4 RECENT DEVELOPMENT 743
17.13 LUPIN 744
- 17.13.1 COMPANY SNAPSHOT 744
- 17.13.2 REVENUE ANALYSIS 744
- 17.13.3 PRODUCT PORTFOLIO 745
- 17.13.4 RECENT DEVELOPMENT 746
17.14 MEDTRONIC 747
- 17.14.1 COMPANY SNAPSHOT 747
- 17.14.2 REVENUE ANALYSIS 747
- 17.14.3 PRODUCT PORTFOLIO 748
- 17.14.4 RECENT DEVELOPMENT 748
17.15 OXFORD LABORATORIES PVT. LTD. 749
- 17.15.1 COMPANY SNAPSHOT 749
- 17.15.2 PRODUCT PORTFOLIO 749
- 17.15.3 RECENT DEVELOPMENT 749
17.16 PENUMBRA, INC. 750
- 17.16.1 COMPANY SNAPSHOT 750
- 17.16.2 REVENUE ANALYSIS 750
- 17.16.3 PRODUCT PORTFOLIO 751
- 17.16.4 RECENT DEVELOPMENT 751
17.17 PFIZER INC. 752
- 17.17.1 COMPANY SNAPSHOT 752
- 17.17.2 REVENUE ANALYSIS 752
- 17.17.3 PRODUCT PORTFOLIO 753
- 17.17.4 RECENT DEVELOPMENT 753
17.18 SANDOZ GROUP AG (SUBSIDIARY OF NOVARTIS AG) 754
- 17.18.1 COMPANY SNAPSHOT 754
- 17.18.2 REVENUE ANALYSIS 754
- 17.18.3 PRODUCT PORTFOLIO 755
- 17.18.4 RECENT DEVELOPMENT 755
17.19 TEVA PHARMACEUTICALS USA, INC. 756
- 17.19.1 COMPANY SNAPSHOT 756
- 17.19.2 REVENUE ANALYSIS 756
- 17.19.3 PRODUCT PORTFOLIO 757
- 17.19.4 RECENT DEVELOPMENT 757
17.20 VIATRIS INC. 758
- 17.20.1 COMPANY SNAPSHOT 758
- 17.20.2 REVENUE ANALYSIS 758
- 17.20.3 PRODUCT PORTFOLIO 759
- 17.20.4 RECENT DEVELOPMENT 759

18 QUESTIONNAIRE 760

19 RELATED REPORTS 764

LIST OF FIGURES

FIGURE 1 GLOBAL STROKE MARKET: SEGMENTATION 88
FIGURE 2 GLOBAL STROKE MARKET: DATA TRIANGULATION 91
FIGURE 3 GLOBAL STROKE MARKET: DROC ANALYSIS 92
FIGURE 4 GLOBAL STROKE MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 93
FIGURE 5 GLOBAL STROKE MARKET: COMPANY RESEARCH ANALYSIS 93
FIGURE 6 GLOBAL STROKE MARKET: INTERVIEW DEMOGRAPHICS 96
FIGURE 7 GLOBAL STROKE MARKET: DBMR MARKET POSITION GRID 97
FIGURE 8 GLOBAL STROKE MARKET: MARKET APPLICATION COVERAGE GRID 98
FIGURE 9 GLOBAL STROKE MARKET: VENDOR SHARE ANALYSIS 99
FIGURE 10 GLOBAL STROKE MARKET: SEGMENTATION 103
FIGURE 11 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASE IS EXPECTED TO DRIVE THE GLOBAL STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2023 TO 2030 104
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL STROKE MARKET IN THE FORECAST PERIOD OF 2023 & 2030 104
FIGURE 13 NORTH AMEIRCA IS EXPECTED TO DOMINATE THE GLOBAL STROKE MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030 105
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR STROKE MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030 106
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL STROKE MARKET 116
FIGURE 16 GLOBAL STROKE MARKET: BY TYPE, 2022 127
FIGURE 17 GLOBAL STROKE MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 128
FIGURE 18 GLOBAL STROKE MARKET: BY TYPE, CAGR (2023-2030) 128
FIGURE 19 GLOBAL STROKE MARKET: BY TYPE, LIFELINE CURVE 129
FIGURE 20 GLOBAL STROKE MARKET: BY TREATMENT, 2022 135
FIGURE 21 GLOBAL STROKE MARKET: BY TREATMENT, 2023-2030 (USD MILLION) 136
FIGURE 22 GLOBAL STROKE MARKET: BY TREATMENT, CAGR (2023-2030) 136
FIGURE 23 GLOBAL STROKE MARKET: BY TREATMENT, LIFELINE CURVE 137
FIGURE 24 GLOBAL STROKE MARKET: BY DIAGNOSIS, 2022 166
FIGURE 25 GLOBAL STROKE MARKET: BY DIAGNOSIS, 2023-2030 (USD THOUSAND) 167
FIGURE 26 GLOBAL STROKE MARKET: BY DIAGNOSIS, CAGR (2023-2030) 167
FIGURE 27 GLOBAL STROKE MARKET: BY DIAGNOSIS, LIFELINE CURVE 168
FIGURE 28 GLOBAL STROKE MARKET: BY GENDER, 2022 174
FIGURE 29 GLOBAL STROKE MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 175
FIGURE 30 GLOBAL STROKE MARKET: BY GENDER, CAGR (2023-2030) 175
FIGURE 31 GLOBAL STROKE MARKET: BY GENDER, LIFELINE CURVE 176
FIGURE 32 GLOBAL STROKE MARKET: BY END USER, 2022 180
FIGURE 33 GLOBAL STROKE MARKET: BY END USER, 2023-2030 (USD THOUSAND) 181
FIGURE 34 GLOBAL STROKE MARKET: BY END USER, CAGR (2023-2030) 181
FIGURE 35 GLOBAL STROKE MARKET: BY END USER, LIFELINE CURVE 182
FIGURE 36 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, 2022 188
FIGURE 37 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 189
FIGURE 38 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 189
FIGURE 39 GLOBAL STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 190
FIGURE 40 GLOBAL STROKE MARKET: SNAPSHOT (2022) 195
FIGURE 41 GLOBAL STROKE MARKET: COMPANY SHARE 2022 (%) 709
FIGURE 42 NORTH AMERICA STROKE MARKET: COMPANY SHARE 2022 (%) 710
FIGURE 43 EUROPE STROKE MARKET: COMPANY SHARE 2022 (%) 711
FIGURE 44 ASIA-PACIFIC STROKE MARKET: COMPANY SHARE 2022 (%) 712